For the final episode of The Deep Dive this week, we sit down with Sina Habibi, CEO of Cognetivity Neurosciences (CSE: CGN). Sina Habibi joins us to discuss Alzheimer’s disease, what lead to the development of Cognetivity and how the tech works, the challenges in having new medical tech adopted, and its recent partnership with InterSystems among other items.
Cognetivity is a tech firm that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Through the use of AI and machine learning, the tech is able to detect the early onset of Alzheimer’s and dementia through testing the performance of large areas of the brain. The tech has acquired regulatory approval for use in both the UK and Europe, with further approvals in North America anticipated to occur.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
Bank Of America Lowers Gold Price Target To $2000? – The Daily Dive feat John-Mark Staude
Returning to the Daily Dive today is that of John-Mark Staude of Riverside Resources (TSXV:...